课题基金 / 基金详情

Developing a novel allogeneic chimeric antigen receptor-modified double-negative T cell (CAR-DNT) therapy for the treatment of chemotherapy-resistant CD4+ T-cell acute lymphoblastic leukemia (T-ALL)

Developing a novel allogeneic chimeric antigen receptor-modified double-negative T cell (CAR-DNT) therapy for the treatment of chemotherapy-resistant CD4+ T-cell acute lymphoblastic leukemia (T-ALL)
开发一种新型同种异体嵌合抗原受体修饰双阴性 T 细胞 (CAR-DNT) 疗法，用于治疗化疗耐药的 CD4 T 细胞急性淋巴细胞白血病 (T-ALL)
批准号：
411303
负责人：
Vasic Daniel
金额：
$1.27万
依托单位：
University of Toronto
依托单位国家：
加拿大
项目类别：
Studentship Programs
财政年份：
2018
资助国家：
加拿大
项目状态：
已结题
起止时间：
2018-12-01 至 2019-12-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=411303&lang=en
关键词：
Healthy-Donor Derived Immunotherapy Adoptive Cellular Therapy Allogeneic Cancer Immunotherapy Chimeric Antigen Receptor-Modified T Cells Double-Negative T Cells Leukemias Novel Immunotherapy Off-The-Shelf Immunotherapy T-Cell Acute Lymphoblastic

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Lasting remissions from induction chemotherapy for T-cell acute lymphoblastic leukemia (T-ALL) are rare and long-term survival for relapsed patients is below 7%. There is an unmet need for a safer and more effective treatment for chemotherapy-resistant T-
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金